

etranacogene dezaparovec (Hemgenix®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2649	for the treatment of severe and moderately severe haemophilia B (congenital factor IX deficiency) in adult patients without a history of factor IX inhibitors.	Not routinely available as the ADTC is waiting for further advice from local clinical experts	12/08/2024	25/10/2024
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/8524/etranacogene-dezaparovec-hemgenix-final-july-2024-amended-070824-for-website.pdf				

trifluridine/tipiracil (Lonsurf®)

SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2654	in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents.	Available in line with local or regional guidance	12/08/2024	25/10/2024
Other Decision Specified :				
Web Link : https://scottishmedicines.org.uk/media/8523/trifluridine-tipiracil-lonsurf-final-july-2024-for-website.pdf				

fezolinetant (Veoza®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2702	treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.	Not routinely available as not recommended for use in NHS Scotland	12/08/2024	12/08/2024
Other Decision Specified : Non-submission				
Web Link : https://scottishmedicines.org.uk/media/8525/fezolinetant-veoza-non-sub-final-july-2024-for-website.pdf				
nivolumab (Opdivo®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2704	Adjuvant treatment of adults and adolescents 12 years of age and older with Stage IIB or IIC melanoma.	Not routinely available as not recommended for use in NHS Scotland	12/08/2024	12/08/2024
Other Decision Specified : Non-submission				
Web Link : https://scottishmedicines.org.uk/media/8520/nivolumab-opdivo-non-sub-final-july-2024-for-website.pdf				

talquetamab (Talvey®)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2705	As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.	Not routinely available as not recommended for use in NHS Scotland	12/08/2024	12/08/2024
Other Decision Specified : Non-submission				
Web Link : https://scottishmedicines.org.uk/media/8521/talquetamab-talvey-non-sub-final-july-2024-for-website.pdf				
trastuzumab deruxtecan (Enhertu)				
SMC Drug ID	Conditions	Decision	Date published on SMC Website	Date of decision / Expected date of decision
SMC2706	As monotherapy is indicated for the treatment of adult patients with advanced NSCLC whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.	Not routinely available as not recommended for use in NHS Scotland	12/08/2024	12/08/2024
Other Decision Specified : Non-submission				
Web Link : https://scottishmedicines.org.uk/media/8522/trastuzumab-deruxtecan-enhertu-non-sub-final-july-2024-amended-070824-for-website.pdf				